Aromatase Inhibitors (AIs) Versus Not (Placebo/Observation) as Late Extended Adjuvant Therapy for Postmenopausal Women with Early Stage Breast Cancer (BC): Overviews of Randomized Trials of AIs after similar to 5 Years of Tamoxifen

Slični predmeti

• Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen
  od: Dowsett, M, i dr.
  Izdano: (2009)
• Variation in use of adjuvant tamoxifen.
  od: Davies, C, i dr.
  Izdano: (1998)
• Cost-effectiveness of Tamoxifen, Aromatase Inhibitor, and Switch Therapy (Adjuvant Endocrine Therapy) for Breast Cancer in Hormone Receptor Positive Postmenopausal Women in India
  od: Butani D, i dr.
  Izdano: (2021-11-01)
• Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer: meta-analysis of quality-adjusted survival.
  od: Gelber, R, i dr.
  Izdano: (1996)
• Aromatase inhibitors versus tarnoxifen as adjuvant therapy for postmenopausal women with estrogen receptor positive breast cancer: meta-analyses of randomized trials of monotherapy and switching strategies
  od: Ingle, J, i dr.
  Izdano: (2009)